×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PBYI – puma biotechnology inc (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PBYI
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
12:32 pm
pbyi
PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer [Yahoo! Finance]
Low
Report
PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer [Yahoo! Finance]
11/20
11:38 am
pbyi
Puma Biotechnology, Inc. (NASDAQ: PBYI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Medium
Report
Puma Biotechnology, Inc. (NASDAQ: PBYI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
11/20
09:03 am
pbyi
Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer [Yahoo! Finance]
Low
Report
Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer [Yahoo! Finance]
11/20
08:57 am
pbyi
Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Medium
Report
Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
11/14
07:09 am
pbyi
We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative [Yahoo! Finance]
Low
Report
We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative [Yahoo! Finance]
11/11
11:13 pm
pbyi
Puma Biotechnology, Inc. (NASDAQ: PBYI) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Medium
Report
Puma Biotechnology, Inc. (NASDAQ: PBYI) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
11/9
09:28 am
pbyi
Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
High
Report
Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/8
12:31 pm
pbyi
Puma Biotechnology, Inc. (NASDAQ: PBYI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Medium
Report
Puma Biotechnology, Inc. (NASDAQ: PBYI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
11/14
12:12 pm
pbyi
Form SCHEDULE 13G/A PUMA BIOTECHNOLOGY, INC. Filed by: ACORN BIOVENTURES, L.P.
Low
Report
Form SCHEDULE 13G/A PUMA BIOTECHNOLOGY, INC. Filed by: ACORN BIOVENTURES, L.P.
11/8
05:33 pm
pbyi
Form SC 13G PUMA BIOTECHNOLOGY, INC. Filed by: BlackRock, Inc.
High
Report
Form SC 13G PUMA BIOTECHNOLOGY, INC. Filed by: BlackRock, Inc.
11/7
04:50 pm
pbyi
Form 10-Q PUMA BIOTECHNOLOGY, INC. For: Sep 30
High
Report
Form 10-Q PUMA BIOTECHNOLOGY, INC. For: Sep 30
11/7
04:18 pm
pbyi
Form 8-K PUMA BIOTECHNOLOGY, INC. For: Nov 07
Low
Report
Form 8-K PUMA BIOTECHNOLOGY, INC. For: Nov 07
10/22
03:25 pm
pbyi
Form SC 13G PUMA BIOTECHNOLOGY, INC. Filed by: BlackRock, Inc.
Low
Report
Form SC 13G PUMA BIOTECHNOLOGY, INC. Filed by: BlackRock, Inc.
9/16
09:02 am
pbyi
Form 8-K PUMA BIOTECHNOLOGY, INC. For: Sep 12
Medium
Report
Form 8-K PUMA BIOTECHNOLOGY, INC. For: Sep 12
8/27
05:03 pm
pbyi
Form S-8 PUMA BIOTECHNOLOGY, INC.
Medium
Report
Form S-8 PUMA BIOTECHNOLOGY, INC.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/4
Form 4 PUMA BIOTECHNOLOGY, INC. For: Feb 03 Filed by: BRYCE RICHARD PAUL
40.3%
2/4 Puma Biotechnology Inc (NASDAQ: PBYI) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 31.6%
11/7 Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 28.5%
11/7 Form 10-Q PUMA BIOTECHNOLOGY, INC. For: Sep 30 25.9%
8/8 Q2/2019 6/30/2019 EPS -0.570 ZacksConsensus -0.900 ActVsEst 0.330 - Beat 25.3%
3/23 Form 8-K PUMA BIOTECHNOLOGY, INC. For: Mar 16 17.3%
4/18 Puma Biotechnology Inc (NASDAQ: PBYI) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 16.3%
12/2 Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries 13.1%
4/3 Form 4 PUMA BIOTECHNOLOGY, INC. For: Apr 02 Filed by: AUERBACH ALAN H 9.7%
3/3 Form 4 PUMA BIOTECHNOLOGY, INC. For: Mar 02 Filed by: AUERBACH ALAN H 9.4%
2/4 Puma Biotechnology Inc (NASDAQ: PBYI) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 31.6%
11/7 Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 28.5%
11/7 Form 10-Q PUMA BIOTECHNOLOGY, INC. For: Sep 30 25.9%
8/8 Q2/2019 6/30/2019 EPS -0.570 ZacksConsensus -0.900 ActVsEst 0.330 - Beat 25.3%
3/23 Form 8-K PUMA BIOTECHNOLOGY, INC. For: Mar 16 17.3%
4/18 Puma Biotechnology Inc (NASDAQ: PBYI) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 16.3%
12/2 Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries 13.1%
4/3 Form 4 PUMA BIOTECHNOLOGY, INC. For: Apr 02 Filed by: AUERBACH ALAN H 9.7%
3/3 Form 4 PUMA BIOTECHNOLOGY, INC. For: Mar 02 Filed by: AUERBACH ALAN H 9.4%
TOP News Decliners
5/9
Puma Biotechnology Reports First Quarter 2019 Financial Results
-41.8%
10/8 Puma Biotechnology Inc (NASDAQ: PBYI) was downgraded by analysts at Goldman Sachs Group Inc from a "neutral" rating to a "sell" rating. They now have a $8.00 price target on the stock, down previously from $24.00. -18.8%
3/14 Puma Biotechnology Inc (NASDAQ: PBYI) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -16.0%
12/2 Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer -14.3%
5/1 Puma Biotechnology Inc (NASDAQ: PBYI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock. -9.7%
9/25 Puma Biotechnology to Present at Cantor Global Healthcare Conference -9.3%
5/10 Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -9.2%
2/20 Form 8-K PUMA BIOTECHNOLOGY, INC. For: Feb 20 -9.0%
11/13 Form 3 PUMA BIOTECHNOLOGY, INC. For: Nov 12 Filed by: Miller Ann Calby -9.0%
4/27 Form DEF 14A PUMA BIOTECHNOLOGY, INC. For: Jun 09 -8.4%
10/8 Puma Biotechnology Inc (NASDAQ: PBYI) was downgraded by analysts at Goldman Sachs Group Inc from a "neutral" rating to a "sell" rating. They now have a $8.00 price target on the stock, down previously from $24.00. -18.8%
3/14 Puma Biotechnology Inc (NASDAQ: PBYI) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -16.0%
12/2 Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer -14.3%
5/1 Puma Biotechnology Inc (NASDAQ: PBYI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock. -9.7%
9/25 Puma Biotechnology to Present at Cantor Global Healthcare Conference -9.3%
5/10 Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -9.2%
2/20 Form 8-K PUMA BIOTECHNOLOGY, INC. For: Feb 20 -9.0%
11/13 Form 3 PUMA BIOTECHNOLOGY, INC. For: Nov 12 Filed by: Miller Ann Calby -9.0%
4/27 Form DEF 14A PUMA BIOTECHNOLOGY, INC. For: Jun 09 -8.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: